Trump orders FDA to expedite review of psychedelics as breakthrough therapies

Former President Donald Trump on Saturday signed a significant executive order that directs the Food and Drug Administration (FDA) to expedite the review of certain psychedelics. Esses compounds had previously been designated as breakthrough therapy drugs. The measure aims to reform access to new medical research and treatments, especially those based on psychedelic substances that are in advanced phases of clinical trials in Estados Unidos.
The initiative, described by Trump as a “historic moment”, seeks to drastically speed up the process of evaluating these therapies. Former President Segundo, these experimental treatments have demonstrated considerable potential for transforming the lives of individuals facing serious mental illness and depression. Concern for the mental health of war veterans was a central point in the justification for signing the order.
Entraves bureaucratic and data sharing
One of the pillars of the executive order is the elimination of unnecessary bureaucratic obstacles. Este aspect is crucial so that research with psychedelics can advance without excessive delays. The initiative also aims to improve data sharing between the FDA and Departamento of Assuntos of Veteranos (VA).
Essa collaboration between federal agencies is seen as fundamental to consolidating existing scientific knowledge and optimizing future studies. The rapid reclassification of any FDA-approved psychedelic drugs is another primary goal of the order. The intention is to ensure that, once their safety and effectiveness are proven, these substances can be made available more quickly to patients.
Ibogaína in focus: potential and investments
One of the psychedelics specifically mentioned by the former president was ibogaine. Trump cited a 2024 study by Universidade of Stanford involving 30 special operations veterans suffering from traumatic brain injuries. The results showed that these veterans experienced an 80% to 90% reduction in symptoms of depression and anxiety within a month of treatment with the substance. The impressive data underscores the therapeutic potential that ibogaine can offer vulnerable populations.
Investments in research into ibogaine were also highlighted. The state of Texas has already allocated 50 million dollars for local studies. The federal government, in turn, announced its own investment of 50 million dollars for research in the area.
- Principais points of research and investment in ibogaine:
- Estudo of Stanford with 30 special operations veterans.
- Redução of 80-90% in symptoms of depression and anxiety.
- Investimento $50 million from Texas state for research.
- Investimento additional US$50 million from the federal government.
Esses investments represent a growing recognition of the potential of psychedelics for treating mental health conditions. The release of funds demonstrates a financial commitment to exploring new therapeutic approaches.
The “Right of Tentar” and access to treatments
The executive order also paves the way for ibogaine to be administered to seriously ill patients in accordance with the “Right to Tentar” law. Esta legislation allows patients with terminal or life-threatening illnesses who have exhausted approved treatment options to access experimental medicines that have not yet been fully approved by the FDA. The measure aims to provide hope and a path to treatment for those in the most desperate situations.
The decision ensures that people suffering from debilitating symptoms can have a chance to reclaim their lives. The expectation is that they will be able to lead happier and more productive lives. The “Right of Tentar” is a legislative tool that gains relevance in the context of innovative therapies.
The next steps in regulation for psychedelics
With the executive order, the FDA will be tasked with intensifying its review of psychedelics already designated as breakthrough therapies. Este process involves rigorous analysis to ensure the safety and effectiveness of each treatment. The ultimate goal is to integrate these substances into the medical arsenal, always under appropriate supervision and regulation. The president reinforced that these experimental treatments are in advanced stages of clinical trials to ensure they are safe and effective for American patients. The FDA, as the lead drug regulatory agency in the US, will play a crucial role in determining how and when these treatments will be made available to the public.






